By integrating mathematical modeling with in vitro experiments we show that treatment-induced autophagy modulates melanoma treatment response, and that adding outcomes data from a companion clinical trial allows implementation of phase i trials (virtual, informed clinical trials) for melanoma combination therapy. 2 Abstract: The combination of chemotherapy and an AKT inhibitor in patients with metastatic solid tumors including melanomas was tested in a recently completed phase 1 clinical trial. Our experiments showed that such regimens differentially induce autophagy in melanoma cells and autophagy modulates the response to treatment. Motivated by these observations, we formulated a mathematical model comprised of a system of ordinary differential equations that explains the dynamics of the response of melanoma cells to different mono and combination therapies. Model parameters were estimated using an optimization algorithm that minimizes differences between predicted cell populations and experimentally measured cell numbers. The model predicts that the combination therapy treatment protocol used in the trial is effective in short term tumor control but that the treatment will eventually fail, although smarter schedules can be applied to extend response. To move this model forward into a more clinically relevant setting, we implemented a phase i trial (a virtual/imaginary yet informed clinical trial), where a genetic algorithm was used to generate a cohort of virtual patients that captured the diversity of disease response observed in a comparable clinical trial. Simulated clinical trials with the cohort and sensitivity analysis defined parameters that discriminated virtual patients having more favorable versus less favorable outcomes. These analyses established the relevance of selecting patients based on rates of tumor growth and autophagic flux. Finally, the model predicts optimal therapeutic approaches across all virtual patients, laying the foundation for phase i-informed clinical melanoma trials. The specific melanoma model developed here is
just one example of the much broader potential of the phase i framework, which can be applied to almost any parameterized cancer model.
Introduction
Significant advances have been made in understanding mechanisms that provoke tumor initiation and progression, and often this knowledge has been translated into the development of targeted agents that selectively disable the mutated, activated and/or overexpressed oncoproteins manifest in tumor cells (1). Most of these targeted agents have been tested in clinical trials either alone or in combination with other treatments (2) , and though some are clinically effective (e.g., small molecule BRAF kinase inhibitors (3)), the majority are not (4, 5) , despite the fact that such agents have potent activity in preclinical cancer cell and animal model studies. This inconsistency is in part due to difficulties in predicting the long--term effectiveness of a cancer therapy using time--limited in vitro (typically < 1 month) or in vivo (often < 3 months) models systems.
We reasoned that an appropriately defined and parameterized mathematical model, based on observations in cell and animal studies and clinical trials, might reveal insights regarding the design of improved and informed therapeutic approaches for treating cancer patients. To test this notion we used a clinically relevant mathematical model of melanoma that was generated based on data from in vitro experiments and from a comparable clinical trial, to predict long--term treatment responses in both cells and patients. A recently completed multi--arm phase 1 trial of the MK2206 AKT inhibitor (AKTi) in combination with standard chemotherapy (chemo) (6) with advanced solid tumors, including melanomas, was used for these studies (Fig. 1A) . To investigate potential mechanisms of treatment efficacy, a mathematical model comprised of a system of ordinary differential equations was developed to describe the dynamics of melanoma cells exposed to four treatment conditions, no treatment, chemo, AKTi and combination of chemo and AKTi. Cell culture experiments were then used to parameterize the model. The fitted model was further validated using results from an extensive series of cell culture experiments that consider twelve different drug combinations and timings. The validated model was then used to predict the long--term effects of the twelve treatments on melanoma cells, which revealed that all treatments eventually fail, but do so at different rates.
To investigate the long--term effects of therapy in a more clinically relevant setting, we varied model parameters to generate virtual patients that had responses similar to typical clinical trial outcomes (6) . We employed a heuristic search algorithm (genetic algorithm (GA)) to generate a diverse virtual patient cohort consisting of over 3,000 patients. Treatment responses for this patient cohort were simulated and optimized, and the schedules of AKTi therapy were combined with chemotherapy. This strategy allowed implementation of a "virtual clinical trial" (phase i trial), where the model guides optimal treatment strategies for selected patient cohorts (7) . Similar virtual clinical trials have been made to simulate clinical trials of cardiovascular disease, hypertension, diabetes (www.entelos.com), and acute inflammatory diseases (8) , but not in cancer. Statistical approaches based on clinical drug metabolism (e.g., dose--concentration relationships) have also been developed to design virtual clinical trials (reviewed in (9) ) that detect significant differences between treatments (for example, placebo vs. treatment). Here we rather sought to translate biological findings coming from in vitro and clinical studies, using melanoma combination therapy, into a phase i trial --with the goal that this approach could be easily adapted to other cancers.
Results

Responses of melanoma treated with combination therapy
We reported unexpectedly long--term responses (of up to 15 months) to the combination therapy of chemo and AKTi in two BRAF--wild type melanoma patients in the trial (NCT00848718) (10) . Although little was known regarding why this combination therapy was successful, but we reasoned this reflected differential effects on inducing autophagy that were observed (10) ( Fig. 1B) , as autophagy represents a cancer cell--intrinsic mechanism of resistance that allows cells to survive times of drug--induced stress (11, 12) or, if uncontrolled, can deplete key cellular components and provoke tumor cell death (13, 14) . The differential autophagic responses to the chemo plus AKTi combination and accompanying effects on tumor cell growth and survival were manifest in melanoma cells ( Fig. 1B) (10) .
Mathematical model development
Motivated by these experimental results, we formulated a mathematical model comprised of three phenotypic compartments ( Fig. 2A(a) ), a non--autophagy compartment (N) and two autophagy compartments (P and Q). We divided the autophagy compartment into two, physiological autophagy (P) and non--physiological autophagy (Q) compartments, based on studies which showed that some cells where autophagy is manifest continue to maintain normal cell homeostasis whereas others did not (15, 16) . Figure 2A 
Model prediction and calibration against preclinical data
The fitted model was used to predict the effects of twelve treatment schedules that differed in the timing and order of chemo, AKTi and combination therapy across a 16--day period (#2) and two applications reduced the population by 50--90% (#3). One application of AKTi had limited impact on tumor cell growth (approximately 20% reduction from #1 to #4).
Continuous application of the AKTi reduced the tumor cell population size by 40--70% (#5).
The M257 melanoma cell line was more sensitive to both chemo and AKTi than WM3918 melanoma cells. Combination therapies were substantially more effective than mono-therapies. In general, concurrent therapies with chemo and AKTi (#6 and #7) were more successful than all sequential therapies (#8--#12). Concurrent therapy #6 reduced the tumor cell population size by up to 90%, and concurrent therapy #7 nearly eradicated all of the tumor cells ( Fig. 2C , #7, nearly invisible red bars). Sequential therapy decreased the tumor cell population size by 50--90% ( Fig 2C #8 --#12).
To validate these predictions, an extensive series of in vitro experiments were performed and the numbers of tumor cells were quantified on day 16 ( Fig.  S1B ). We then compared the total experimental melanoma cell numbers with those predicted by the models (Fig. 2C , blue vs. red bars). In general, the predictions matched well with the experimental results, as all predicted values (red bars) were within one standard error deviation from the mean value of the experimental results (blue bars). Thus, this mathematical model accurately describes and predicts treatment outcomes manifest in vitro.
Long-term response of treatments
Having established a successfully calibrated model, the longer--term effects of the therapies were assessed. Surprisingly, the best proposed strategy (#7) failed by day 40 (WM3918 cells) or day 50 (M257 melanoma), where the physiological autophagy phenotype developed resistance to the therapy population (green lines, Fig. S2 ). This finding highlights a key shortcoming of in vitro experiments; i.e., the limited timescale. Thus long--term studies were performed. As predicted, a 30--day treatment of strategy (#7) failed to eradicate some of the melanoma cell lines in colony formation assay experiments (10) .
Phase i trial: virtual cohort generation
Under the assumption that our underlying model of the autophagy model mechanism is relevant to the clinic, and there is some evidence to support this (17) , it was important to advance such analyses beyond homogeneous cell lines to the heterogeneous patient population. More specifically, in order to predict long--term treatment responses in a more clinically relevant scenario, treatments for model parameters that are more representative of real patients were simulated. The same treatment schedules as in the clinical trial (6) were used, with five cycles of first--day chemo in a 21--day cycle, and two different treatment arms of AKTi schedules (Q3W, QOD). In the first AKTi schedule (arm 1: Q3W), the drug is administered on the first day of the 21--day cycle for five cycles, and thereafter is given on the first day of every week (weekly maintenance therapy). In the second schedule (arm 2: QOD), the drug is administered on days 1, 3, 5 and 7 of the 21--day cycle, and is then given weekly as maintenance therapy.
To generate virtual patient cohorts that exhibit the diversity of responses observed in the clinic, adaptive heuristic search GA algorithms (built in Matlab) were used, which are based on the evolutionary principle of natural selection (18, 19) . A solution
, using the difference between tumor volume with a parameter ( ) and the target tumor volume ( ! ). The ! was randomly selected from three categories ( ! , ! , ! ), where subscript denotes complete response (CR; tumor diameter < 1 mm), subscript denotes partial response (PR; at least 30% reduction in tumor diameter) and subscript denotes stable disease (SD; up to 20% increase in tumor diameter), based on response criteria (20) . Our GA found 1293 sets of parameters in the case of arm 1 (P1) and found 2098 sets of parameters for arm 2 (P2).
Phase i trial: Stratifying treatment outcomes via clinically measurable parameters
To characterize this virtual cohort, it was first divided into four sub--cohorts (C1--C4, Fig.   3A (a)) according to parameter values ( ! , ! ), which are clinically measurable variables (chemo--sensitivity (21, 22) , and autophagy marker staining (23, 24) ) was used to predict best responders and worst responders. We compared a distribution of best tumor volume change responses of the 24 patients in the trial with that of 500 virtual patients sampled from our virtual cohort (3391 virtual patients) ( Fig. 3A(b) ). To test if two distributions are from the same continuous distribution, we performed a two--sample Kolmogorov--Smirnov test (Matlab statistics toolbox) (25) . The test determined that we cannot reject the null hypothesis at 5% significance (H = 0, P > 0.05, test statistic = 0.14). Empirical cumulative distribution functions of the two overlap each other ( Fig. 3A(b) ). This implies that the best tumor volume responses of these 500 virtual patients can recapitulate real patients' tumor volume response well. To validate the agreement further, we used Lin's concordance correlation coefficient (ρ) (26, 27) . We repeatedly sampled 24 virtual patients with an approximated probability density function of best tumor volume changes of real patients Overall, tumors in the P2 group grew much faster than those in P1 (mean of ~30 days vs.
mean of ~60 days, respectively). In P1, tumors in C1 (dark blue) and C2 (dark green) that had slightly increased autophagy following AKTi treatment grew faster than those in C3
(orange) and C4 (pink) that had highly increased levels of autophagy (50 days vs. 70 days).
In contrast, there were no significant differences in the doubling times between the sub-cohorts in P2.
Phase i combination therapy was simulated for 6 months with the two arms to predict treatment responses in the virtual cohorts. Patients in P1 treated with arm 1 had diverse responses to the therapy, where CR, PR and SD were observed in 30 randomly selected subjects ( Fig. 3B(a) , waterfall plot). For example, some patients in C1 were expected to be complete responders (CR, dark blue bars of nearly --100%), while others in the same cohort were expected to be in SD (dark blue bars of 40--60%). When comparing the expected tumor volume changes in each cohort ( Fig 3B(a) , middle boxplot), there were no significant differences in outcomes between C1 and C2 or between C3 and C4. However, the C2 and C3 cohorts showed a significant difference (P <0.01, Student's t--test). Thus, one of the parameters, specifically the physiological autophagy phenotype ( ! ), defines outcome. The histogram of all subjects in each cohort also showed a shift in treatment responses from the cohort C1--2 (skewed toward responsive) to C3--4 (uniformly distributed tumor volumes).
Similarly, subjects in P2 treated with arm 2 also showed diverse responses to therapy ( Fig. 3B(b) ). However, unlike subjects in P1 ( Fig. 3B(a) ), none of the metrics determined outcomes of subjects in P2, as the mean tumor volume responses in the four cohorts did not show significant differences ( Fig. 3B(b) , boxplot). Accordingly, the histograms only showed a slight shift of responses when C1--3 was compared to C4 ( Fig.   3B (b)).
We also randomly assigned a treatment arm (either arm 1 or arm 2) to all virtual patients in both P1 and P2. Tumor volume was checked at the beginning of each cycle (every 21 days), and subjects were removed from treatment if the tumor volume had more than doubled; this resulted in the removal of a total of 1473 subjects. Random assignment of the treatment arms produced even greater variations in expected outcomes ( Fig. 3B(c) ), but might more accurately reflect how an actual population responds. Specifically, the expected tumor volume changes showed a large variation, where the 9--99% bar in the boxplot increased in all sub--cohorts, and in both arms. The physiological autophagy phenotype ( ! ) distinguished outcomes between C2 and C3 only when patients were treated with arm 2 (Fig.  3B (c), boxplot, P <0.05). There was no shift in the distribution of responses between the cohorts ( Fig.  3B(c) , histograms). Interestingly, the outcomes were almost uniformly distributed in patients treated with arm 1, while the distributions of patients treated with arm 2 were skewed toward smaller final tumor volumes (more responsive to the therapy). Thus, the physiological autophagy phenotype defines outcomes in diverse virtual cohorts.
Phase i trial: Assessing stratification factors by sensitivity analysis
Rather than focusing solely on the clinically quantifiable parameters, the nine remaining model parameters were also assessed to identify sub--cohorts that are most or least likely to benefit from the combination therapy. To identify the key parameters a sensitivity analysis of the effect of each parameter on tumor volume after 6 months of treatment was performed. After dividing the patient group into CR, PR, and SD (based on their tumor volume at 6 months), each parameter value from each group was compared and the Student's t--test was used determine if the mean values of a parameter differed between two groups (CR vs. PR and PR vs. SD) ( Fig. S4--S6 ). In patients in P1, the two autophagy-associated phenotypes, physiological and non--physiological ( ! , ! ), were significantly different between CR and PR and between PR and SD ( Fig. S4 ). Compared with the previous partition ( Fig.  3A) , the new partitioning of P1 according to the value of ! and ! (Fig.  4A,) discriminated the expected treatment outcomes more clearly. Unlike the previous partition result ( Fig. 3B(a) ), each sub--cohort (C1--4) now showed significantly different mean response to therapy (Fig. 4A, boxplot) . The new sub--cohort C1 (cyan) is most likely to benefit from the treatment, while the likelihood decreased gradually in C2 (blue), C3
(yellow), and C4 (red). There is also a clear shift in the distribution of treatment response from C1 to C4 (Fig. 4A , waterfall plot).
Similarly, our sensitivity analysis on P2 ( Fig. S5 ) revealed another key parameter set ( ! , ! ), the growth rates of both the non--autophagy and physiological autophagy phenotypes. P2 was divided based on the parameter values (C1--C4) ( Fig.  4B,  table) . Unlike the previous partitioning ( Fig. 3B(b) ), these parameters successfully segregated patients according to the expected outcomes ( Fig. 4B, boxplot ). C1 was revealed as the best responding sub--cohort, where almost all tumor volumes in this group (99%) were reduced by at least 20% (Fig. 4B, cyan boxplot) . The next best responders were both C2 and C3,
where more than 75% of the cohorts showed at least a 30% reduction in tumor volume;
the expected outcomes in C2 and C3 significantly differed from those in C1 (P < 0.01). The expected outcomes in C4 were slightly worse than those in C1--C3, as the mean outcome was worse with some tumors from C4 having an increased tumor size of up to ~70% (Fig.  4B , red boxplot). The waterfall plots in Fig. 4B show inter--patient variation in tumor volume changes even within the same sub--cohort and shifting of the treatment response from C1 to C4.
With random treatment assignment of either arm 1 or arm 2 to all patients in both P1 and P2, as would be done in a real trial, our analysis identified the key parameters ! and ! as potential predictive factors of the treatment outcomes (Fig. S6 ). The new cohorts (C1 * --C4 * , Table in Fig. 4C ) exhibit significantly different mean responses to therapy ( Fig. 4C , boxplots). The new partition also showed a tendency of increasing tumor volumes from C1 * to C4 * in both arms (Fig.  4C , boxplots and waterfall plots), and defined the most sensitive sub--cohort (C1 * ), who are predicted to be the most likely to benefit from treatment using either arm 1 or arm 2. In summary, sensitivity analysis allows one to select potential predictive factors for each treatment strategy, which could be used as a guide for selecting specific therapies for a given patient.
Phase i trial: Optimizing AKTi treatment to minimize toxicity for each sub-cohort
For the new virtual sub--cohorts (C1 * --C4 * ) optimal therapy recommendations were derived using implicit filtering (30) . Notably, the schedule of chemo was fixed, as it was in the clinical trial (6), with the goals of identifying the AKTi schedule that reduced the initial tumor volume by at least 30% after 6 months of therapy, and that used as few AKTi applications as possible to provide an effective and less toxic treatment strategy. Optimized schedules of AKTi are summarized in Table 1 . For the patients in C1 * , optimum therapy recommended 1 day of AKTi treatment on the first day of the 42--day cycle, a treatment holiday for five cycles and then from day 168, 1 day of treatment on the first day of a 7--day cycle (weekly maintenance). For the patients in C2 * , the optimal schedule was to administer
AKTi on the first and third days of a 21--day cycle for five cycles, followed by weekly maintenance. For the patients in C3 * , optimization recommended that AKTi be taken on the first, third, and fifth days of each 19--day cycle for five cycles, followed by administration on the first day of each week from day 95. The optimal schedule for cohort C4 * is to administer AKTi on the first, third, and fifth days of each 19--day cycle for five cycles, followed by administration on the first and third days of a 9--day cycle from day 96.
To understand the relative impact of these alternate therapies we compared the 2--
year survival probability of patients on the different therapies. The therapies included optimized therapy, treatment arm 1 and arm 2, and two mono--therapies of AKTi only (i.e., AKTi treatment only from either arm 1 or arm 2), and chemo (Fig. 5 ). The initial number of tumor cells was set at one billion and the melanoma was considered fatal when the number of tumor cells reached 10 13 cells. We also compared the cumulative drug concentration of each therapy to determine the toxicity of the treatment at two time points, immediately after the five--cycles of combination therapy of AKTi with chemo (105 days) and at the completion of therapy (2 years) (see Materials and Methods for calculations of plasma concentration).
As expected, the probability of 2--year survival decreased after 6 months if the patients in the cohort C1 * were not treated with any therapy (Fig. 5A, black line) . Survival of the chemo--alone C1 * cohort had only minimal improvement (Fig. 5A, yellow line) . In contrast if the C1 * patients were treated with any type of AKTi, their probability for 2 year survival remained over 0.9 (Fig. 5A , red, pink, blue, cyan and green lines), which was expected as this cohort is the most sensitive ( Fig. 4C , cyan boxplots, tumor volume at 6 months < --60%). Regarding toxicity, the optimal therapy was the least toxic to patients, as the cumulative drug concentration was minimal ( Fig. 5A, green bars) , except the C1 * chemo cohort ( Fig. 5A , nearly invisible yellow bar).
The probability of 2--year survival of patients in cohort C2 * also decreased after 6 months if patients were not treated with any therapy (Fig. 5B , black line) and chemo again slightly increased the probability of survival ( Fig.  5B,  yellow  line) . Also, like the cohort C1 * , the probability of 2--year survival was relatively high (> 0.9) when patients were treated with any of the AKTi schedules (Fig. 5B ). The combination AKTi with chemo and the optimized therapy slightly increased survival probability (Fig. 5B , cyan, blue, and green lines). Regarding toxicity, arm 2 (cyan) was the most toxic, followed by AKTi (QOD, pink), the optimized therapy (green bar), and arm 1 (blue bar), at both days 105 and 720 (2 years) ( Fig.  5B  bar  graphs) . Interestingly, the most optimized therapy is substantially less toxic than both arm 2 and AKTi (QOD) at day 105.
For patient cohort C3 * , the survival probability decreased rapidly to zero by 6 months if the patients were untreated (Fig. 5C , black line) and chemo again had little--to--no.
impact on survival (Fig. 5C, yellow line) . The AKTi monotherapies and treatment arm 1 significantly improved patient survival (Fig. 5C , AKTi: pink and red lines and arm 1: blue line). However, the most optimized therapy and arm 2 clearly provided the best probability for survival, and again the optimized therapy was less toxic than arm 2 (Fig.  5C , green vs.
cyan bars).
Finally, like the C3 * cohort, the probability of survival of C4 * patients decreased sharply if they were untreated or treated with chemo only (Fig.  5D , black and yellow line), and again the AKTi monotherapies improved survival ( Fig. 5D , red line (Q3W), and pink line (QOD)). Both treatment arm 1 and arm 2 also increased the probability of survival ( Fig.   5D , blue line: arm 1 and cyan line: arm 2). Notably, the optimized therapy significantly improved the probability of survival (Fig. 5D , green line) compared to arm 2 (P < 0.05), and was also less toxic than arm 2 at day 105 right after the five cycles of combination of chemo with AKTi, although it became more toxic at year 2 ( Fig. 5D bar graphs) .
Discussion
The integrated approach applied herein shows that treatment--induced autophagy phenotypes likely account for the long--term effects of treating patients with chemo in combination with AKTi. The mathematical model hypothesizes that two distinct states of autophagy exists (physiological and non--physiological states), and indicates that improved patient outcomes are associated with the non--physiological autophagy phenotype. The model also predicts that therapy drives the transition from the non--autophagy to the physiological autophagy phenotype, and that with continued exposure to AKTi selects for the emergence of the physiological autophagy phenotype that provides a transient escape route from treatments and which we conclude has the greatest fitness under such continuous selection pressure. In contrast, the model indicates that a persistent non-physiological autophagy state is detrimental to overall fitness and thus this represents a desired outcome of therapy.
Implementing a phase i trial allows one to translate models to a clinically relevant setting. The key components of such a trial are a clinically relevant mathematical model and a cohort of virtual patients that mirror responses observed in an actual clinical trial.
When developing mathematical models to facilitate clinical decisions, an important constraint is the number of measurable parameters of the patient. As patient data are generally limiting, this inevitably leads to simpler models, where the data dictate model inputs and consequently, model outputs. The model presented herein is an excellent example, as it is constructed by integrating experimental findings for a given cancer (e.g., melanoma) with the clinical reality. An extensive cohort having widely distributed parameters is another key element of the phase i trial, and the cohort should be representative of inter--patient variability, which drives the diversity of the response (i.e., the spectrum of the response and resistance to a given therapy) that is observed in the clinic. Using a GA and employing response criteria used in the clinic, one can easily generate a relatively large cohort of diverse virtual patients who are treated using the same treatments given to patients in a clinical trial.
To stratify treatment outcomes according to clinically measurable variables, the cohort was divided based on chemo--sensitivity and the induction of autophagy in tumor samples. The rate of transition to the physiological autophagy phenotype was a predictive factor of treatment outcome for arm 1, where higher rates of physiological autophagy resulted in unfavorable outcomes. Interestingly in another melanoma study using different treatments, an increased autophagy response was associated with resistance to BRAF inhibitors (17) . In treatment arm 2, neither of the two variables selected for more sensitive or resistant individuals. However, after randomly assigning treatment of either arm 1 or arm 2 to each virtual patient, the autophagy phenotype again discriminated sensitive vs.
non--sensitive sub--cohorts. Interestingly, some of the good responders to arm 2 became non--responders when their treatment was switched to arm 1 (Fig.  3B(c) , --100% dark blue bars on the far left), highlighting the importance of selecting the most appropriate patients for a given treatment. Sensitivity analysis of the simulated cohort was superior at defining predictive factors in each treatment arm, which discriminated between CR, PR and SD. The ability of non--autophagic melanoma cells to become either physiological or non--physiological autophagic determined patient outcomes for arm 1, whereas the growth rates of proliferating tumor cells (non--autophagy vs. autophagy phenotypes) were the determinants of outcomes for arm 2. Further, when randomly assigning to either arm 1 or arm 2 the transition to the non--physiological autophagy phenotype and the growth rate of non--autophagy cells discriminated outcomes. Thus, key parameters for cases having more or less favorable outcomes can be defined for each treatment schedule, demonstrating the utility of phase i trials in aiding patient selection.
Optimizing the AKTi schedule for each cohort provided the most benefit. Notably, mathematically informed drug scheduling can positively impact overall outcome, including using a lower drug dose in some cohorts. Indeed, changing the temporal protocol influenced the dynamics of the system significantly. Interestingly, another melanoma study showed that using unconventional (discontinuous) dosing schedules of melanoma cells with BRAF inhibitors could prevent resistance (31) . This idea is now being explored in a phase II clinical trial of BRAF--mutant melanoma patients (SWOG: 1320). We submit that the simulation of optimized schedules and comparing outcomes across virtual patients can assist clinical treatment planning to improve overall outcomes (6) .
The underlining mechanisms, parameterization and validation of our model were based on data from a preclinical in vitro study. However, as demonstrated here an integrated approach can be also be achieved using in vivo preclinical studies (32) . To bridge the divide between the in vitro study and the clinic the assumption was made that the same mechanisms of therapy resistance apply. Whilst this oversimplifies the many routes to resistance, for the two drugs and the range of treatment schedules considered, the data establish that this assumption was reasonable, where a companion clinical trial that used the same drugs as our in vitro study generate a virtual patient cohort that matched the distribution of clinically observed outcomes. Thus, using an integrated approach, phase i trials can be broadly applied to improve safety and efficacy of clinical oncology trials, as well as patient outcomes. state. Cells in each compartment die at some rate ( !,!,! ). To model increased cell deaths on days 6--9 ( Fig. 1B(b) ), we included the delayed cell deaths of quiescent/senescent autophagy cells ( ).
Materials and Methods
Mathematical modeling
The effects of chemo, AKTi and their combination ( Fig. 2A(b)--(d) ) were incorporated into the model. It was assumed that the drug reaches its maximum concentration immediately after administration and remains at that level until the beginning of the treatment break. Although the chemotherapeutic agents (paclitaxel and carboplatin) are detectable in patients for 24 hours, the half--life is serum is relatively short, in the range of 5.6 -11.1 hr (33, 34) ; we assumed that the concentration of the chemotherapeutic agents were maintained for only 1 day after administration and became zero at the beginning of the treatment break. As the plasma concentration of AKTi (MK2206) is known to be constant for approximately 48 hr (with a long terminal elimination half-life of 40--100 hr) (35) , we assumed that a 1--day application of AKTi to cells or patients corresponds to a 2--day application to cells or patients in silico. Notably, drug doses were not modulated in this study, where a fixed dose was assumed for both chemo and AKTi. As cell culture experiments showed that chemo triggered cell death with negligible effects on autophagy ( Fig. 1B(a) ), it was assumed that chemo only augmented cell death. Further, as chemo is effective only in proliferating melanoma populations, we assumed that the therapy increases the death rate of the two proliferating phenotypes, non--autophagy ( ! ) and physiological autophagy cells ( ! ) (Fig. 2B(b) , black arrows). We also assumed that the frequency with which cells became quiescent/senescent ( ! ) increased with chemo ( Fig. 2B(b) , black lines). In vitro studies showed that while AKTi did not augment cell deaths or effectively inhibit melanoma cell growth ( Fig. 1B(a) --(b) and (10)), it did induce autophagy (Fig. 1B(c) and (10)); thus, we assumed that AKTi increases the rate of transitioning to the autophagy phenotypes, ! and ! (Fig. 2B(c) , black arrows). As combination therapy does not augment cell death compared with chemo, nor significantly increase autophagy relative to AKTi, the combination of the two treatments was modeled by adding the effects of chemo and AKTi (Fig. 2B(d) , black arrows and crosses). Finally, it was assumed that no cells with a given phenotype revert to their original states while any treatment is being applied. The schematic representation of this compartment model ( Fig. 2A(a) to (d)) converts readily into a system of ordinary differential equations:
In equation (1), ( ) and model time schedules of AKTi and chemo, respectively. To model the treatment schedules, we used Heaviside function − defined by
Assuming alternative application of the AKTi over a period of time at each cycle, the schedule of AKTi was modeled by
, where n is the number of AKTi applications at each cycle, ! is the number of AKTi treatment cycles, and ! is the length of each AKTi treatment cycle. Similarly, the schedule of chemo was modeled by C(t) =
, where ! is the number of chemo cycles, ! is the length of each chemo--cycle, and ! is the duration of chemo.
Parameter estimation
Two melanoma cell lines (M257 and WM3918) were treated with chemo on the first four days (day 0--4) and with AKTi on every other day (days 0, 2, 4, and 6). We measured the number of melanoma cells at days 4, 6 and 8. We assumed that all of the initial tumor cell population was the non-autophagy phenotype (100% of non--autophagy cells on day 0). Both initial cell populations and the growth rate of non--autophagy cells ( ! ) are estimated by assuming an exponential growth of untreated cells and finding both the initial value and exponent of the best--fit curve. We used an optimization algorithm called implicit filtering (30), a steepest descent algorithm for problems with bound constraint, to determine the best remaining parameter set (except ! ) that minimized the difference between predicted number of cells ( ! ) and experimental result ( ! ) in four conditions:
no treatment (n); chemo (c); AKTi (a); and combination (m). The mathematical definition of our problem is:
where the goal is to minimize the objective function f subject to the condition that ∈ ℝ ! is in the feasible region:
where and ! and ! are the upper and lower bound on the jth component ! of the vector H. The estimated parameters for each cell line are summarized in Table S1 .
Synopsis of 12 different schedules over 16 days tested to validate the model
The schedules (Fig. S1 ) included: #1, no--treatment; #2, two types of mono--therapies with chemo only (one time chemo for the first four days, days 0--4); #3, two chemos for both the first four days (days 0--4) and the last four days (days 12--16); #4, AKTi mono--therapy (one time AKTi for the first four days (days 0--4), #5: AKTi mono--therapy, alternative day administration of AKTi.
We considered both concurrent and sequential combination therapies. The two concurrent combination therapy schedules are #6 and #7, where #6 was one time treatment of concurrent therapy for the first four days (day 0--4), and where #7 was one time treatment of chemo for the first 4 days (days 0--4) and alternative administration of AKTi.
The four single agent sequential therapy schedules (#8--#12) included different ordering of chemo and AKTi. Some schedules set chemo treatment first, where #8 was chemo from day 0 to day 4 and then AKTi from day 0 to day 4, whereas #9 was chemo on day 0--4 and then alternating administration of AKTi. The other schedule administrated AKTi first, where #10 was AKTi first for day 0--4 and then chemo day 0--4. Finally, there were alternative applications of chemo and AKTi twice, where #11 was chemo first for the first four days, followed by AKTi treatment for 4 days, and
where #12 was AKTi for the first four days, followed by 4--day application of chemo.
Optimization of AKTi schedules
In the model AKTi was initially administered with chemo for five cycles and then administered without chemo (AKTi maintenance), as in the clinical trial. For each AKTi application, we assumed a denotes each cohort C1--4 * and V0 is the initial number of tumor cells (10 9 cells). We employed the implicit filtering method to find the optimal S for each cohort.
Toxicity treatment: cumulative drug concentration of AKTi and chemo
The plasma concentration of AKTi was determined by solving a differential equation
where is a decay rate of AKTi and ( ) (defined in the above Mathematical modeling section) denotes the application of AKTi. We assumed that the decay rate of AKTi is 0.35 per day based on pharmacokinetic study of AKTi in patients (35) . Similarly, plasma concentration of chemo was obtained by solving a differential equation Box whisker plot of the expected 6-month treatment outcomes in the new sub-cohorts C 1 *-C 4 *.
Waterfall plots of the final tumor volumes in 40 randomly selected 40 patients treated with either arm 1or arm 2 (random assignment). A natural death rate ( ! ) was set to be ! = 0.01. P N → P
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